Last updated 14 days ago
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
490 patients around the world
Available in Argentina, United States, Spain
This study will be performed in 2 parts: Dose Escalation and Confirmation (Part 1) and
Cohort Expansion (Part 2). Following determination of the recommended phase 2 dose (RP2D)
in Part 1, the study plans to proceed with Part 2 using 8 disease-specific expansion
cohorts (Cohorts A to H).
Merck Sharp & Dohme Corp.
9Research sites
490Patients around the world
This study is for people with
Leukemia
Chronic lymphocytic leukemia
Rare diseases
Waldestrom's macroglobulinemia
Lymphoma
Non-Hodgkin lymphoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Recruiting
Centro Oncológico de Integración Regional C.O.I.R.
Recruiting
Centro de Internación e Investigación Clínica FUNDALEU
Recruiting
Hospital Alemán
Recruiting
Instituto Médico de la Fundación Estudios Clínicos - Rosario
Recruiting
Hospital Privado de Córdoba
Recruiting
Hospital das Clínicas da Faculdade de Medicina da São Paulo - USP
Recruiting
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA
Recruiting
Hospital Paulistano
Recruiting
StudyMK-1026-003
SponsorMerck Sharp & Dohme Corp.
Study typeInterventional
Conditions
Chronic lymphocytic leukemiaWaldestrom's macroglobulinemiaNon-Hodgkin lymphoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04728893
